Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lupus nephritis

Phase III ocrelizumab trial halted by infections

A high rate of serious infections in a phase III trial of the anti-CD20 monoclonal antibody ocrelizumab for class III/IV lupus nephritis led to early termination of the study. Thus, despite the partial results (n = 223) suggesting that this drug might have some efficacy—overall renal response rate was improved, although not statistically significantly, in the ocrelizumab group compared with the placebo group (66.9% versus 54.7%)—the risks associated with ocrelizumab use seem to outweigh the benefits for patients with this disease.

ORIGINAL RESEARCH PAPER

  1. Mysler, E. F. et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from the randomized, double-blind phase III BELONG study. Arthritis Rheum. doi:10.1002/art.38037

Download references

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Phase III ocrelizumab trial halted by infections. Nat Rev Rheumatol 9, 444 (2013). https://doi.org/10.1038/nrrheum.2013.98

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.98

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing